Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis.

Abstract

BACKGROUND:

The aim of this study was to assess the efficacy, tolerability and safety of risedronate in adults with CF.

METHODS:

Patients with a lumbar spine (LS), total hip (TH) or femoral neck (FN) bone mineral density (BMD) Z-score of -1 or less were randomised to receive risedronate 35 mg weekly or placebo, and calcium (1g)+vitamin D(3) (800IU).

RESULTS:

At baseline, BMD Z-scores in the risedronate (n=17) and placebo (n=19) groups were similar. By 24 months, 7/17 risedronate patients vs 0/19 placebo patients stopped the study medication due to bone pain. After 24 months treatment, the mean difference (95% CI) in change in LS, TH and FN BMD between the risedronate vs placebo groups was 4.3% (0.4, 8.2) p=0.03; 4.0% (-0.5, 8.6) p=0.08; and 2.4% (-3.5, 8.2) p=0.41.

CONCLUSIONS:

After two years treatment there was a significant increase in LS BMD with weekly risedronate compared to placebo.

• Authors: Charles S Haworth, Linda Sharples, Vikki Hughes, Sarah L Elkin, Margaret E Hodson, Steven P Conway, Christine Etherington, J Stuart Elborn, Jackie Rendall, Ella Wheaton, Emma Kadri, Jane Elliott, Helen C Barker, Philip W P Bearcroft, Thinn Hlaing, Juliet E Compston
• Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society (J Cyst Fibros) Vol. 10 Issue 6 Pg. 470-6 (Dec 2011) ISSN: 1873-5010 [Electronic] Netherlands
• PMID: 21849264 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Chemical References

• Bone Density Conservation Agents
• Risedronic Acid
• Etidronic Acid

Topics

• Adult
• Bone Density (drug effects)
• Bone Density Conservation Agents (administration & dosage, pharmacology)
• Cystic Fibrosis
• Drug Administration Schedule
• Etidronic Acid (administration & dosage, analogs & derivatives, pharmacology)
• Female
• Humans
• Male
• Risedronic Acid
• Single-Blind Method